GlassScriptPhysician profile
Cindy Marika
NPI 1871569004
$2,473.28
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $216 · 2021: $555 · 2022: $267 · 2023: $385 · 2024: $302 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.29 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $307.28 | 2019-2022 | |
| Pfizer INC. | $216.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.56 | 2019-2022 | |
| Lilly USA, LLC | $157.61 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $157.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $149.84 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $144.04 | 2019-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $115.29 | 2019-2021 | |
| Exact Sciences Corporation | $113.50 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $94.60 | 2023-2024 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $76.80 | 2020-2024 | Contrave |
| Abbott Laboratories | $66.77 | 2022-2023 | Proclaim |
| Ars Pharmaceuticals Operations, INC. | $53.32 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $43.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.77 | 2019-2020 | |
| Ibsa Pharma INC. | $28.47 | 2021-2024 | Tirosint, Licart |
| Optinose US, INC. | $26.42 | 2025 | |
| Phadia US INC. | $18.44 | 2023 | Immunocap |
| Shield Therapeutics INC | $16.99 | 2024 | |
| Shire North American Group INC | $16.71 | 2019 | |
| Allergan, INC. | $15.71 | 2020 | |
| Lucid Diagnostics INC. | $13.75 | 2022 | |
| Acella Pharmaceuticals, LLC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Marika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.